BridgeBio's Acoramidis Shows Real-World Edge Over Tafamidis in ATTR-CM Treatment
Event summary
- Acoramidis reduced risk of clinical worsening by 34% compared to tafamidis in ATTR-CM patients (p=0.046).
- Study showed 43% reduction in diuretic intensification, an early marker of worsening heart failure (p=0.021).
- Benefits emerged within weeks of treatment initiation and increased over time in 4.6-month follow-up.
- Results published in Cardiology and Therapy using U.S. claims data from Dec 2024-April 2025.
- Additional independent real-world study expected at upcoming 2026 medical meeting.
The big picture
This study represents the first peer-reviewed, real-world evidence differentiating clinical outcomes between approved TTR stabilizers, positioning acoramidis as a potential frontline treatment option for ATTR-CM. The findings come at a time when demand for effective genetic condition treatments is growing, with BridgeBio aiming to bridge the gap between genetic science and meaningful therapies for underserved patient populations. The competitive dynamics in the TTR stabilizer market will be closely watched as these results could influence treatment guidelines and patient switching.
What we're watching
- Competitive Positioning
- Whether BridgeBio can leverage these results to gain market share against established TTR stabilizers like tafamidis.
- Regulatory Impact
- How upcoming regulatory approvals and label expansions might affect acoramidis's commercial potential.
- Long-term Efficacy
- The pace at which additional long-term data will confirm or challenge these early real-world findings.